Plain-English translation of NCT07047690 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help reduce skin thickening in people with systemic sclerosis. Systemic sclerosis is a condition where the skin becomes thick and stiff, sometimes affecting internal organs too. Researchers want to see if the medication is safe and effective, and to figure out the best dose to use.
Systemic sclerosis causes progressive skin thickening that can significantly impact quality of life, and current treatment options are limited. This trial is exploring whether this new treatment could offer patients a better option to slow or improve skin changes.
You likely qualify if…
You likely don't qualify if…
You would receive injections of either the experimental medication at one of two doses or a placebo (inactive treatment) for 52 weeks. During this year-long study, you would have regular clinic visits where doctors would measure your skin thickness and check how you're doing. You would also have blood tests and other assessments to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States
Switzerland